CFM
CTKB icon

Catalyst Funds Management’s Cytek Biosciences CTKB Stock Holding History

Catalyst Funds Management’s Portfolio CTKB Stock Details CTKB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-2,700
Closed -$15.1K – 1358
2024
Q2 		$15.1K Buy
2,700
+2,400
+800% +$14.4K ﹤0.01% 778
2024
Q1 		$2.01K Buy
+300
New +$2.37K ﹤0.01% 1052

Other funds holding CTKB

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Brown Capital Management Baltimore, Maryland $704M AUM 6.25% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
New York State Common Retirement Fund
New York State Common Retirement Fund Albany, New York $71.6B AUM 29.66% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Catalyst Funds Management's CTKB Position: Q3 2024 in Review

Catalyst Funds Management sold out of Cytek Biosciences (CTKB) in Q3 2024, closing a stake of 2,700 shares — an estimated $15.1K sold.

Catalyst Funds Management first reported a position in CTKB in Q1 2024 and held it in 2 quarters. The position peaked at $15.1K in Q2 2024. 136 funds tracked by Wall St. Rank hold CTKB as of Q3 2024.

  • Catalyst Funds Management reported no remaining Cytek Biosciences position as of Q3 2024 after selling out during the quarter.
  • Catalyst Funds Management sold 2,700 Cytek Biosciences shares in Q3 2024, an estimated $15.1K.
  • Catalyst Funds Management first reported a position in Cytek Biosciences in Q1 2024 and held it in 2 quarters.
  • Catalyst Funds Management's Cytek Biosciences position peaked at $15.1K in Q2 2024.
  • 136 funds tracked by Wall St. Rank held Cytek Biosciences as of Q3 2024.

Based on Catalyst Funds Management's 13F filing for Q3 2024, filed 14 Nov 2024.